Stockreport

AbbVie completes acquisition of Gilgamesh Pharmaceuticals' bretisilocin [Yahoo! Finance]

GH Research PLC - Ordinary Shares  (GHRS) 
PDF Bretisilocin is a novel, short-acting serotonin 5-HT2A receptor agonist and 5-HT releaser currently in Phase 2 clinical development for the treatment of patients with mo [Read more]